Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
about
N-formylation of lysine in histone proteins as a secondary modification arising from oxidative DNA damageTargeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and FutureMechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer CellsDirect but no transgenerational effects of decitabine and vorinostat on male fertilityCrystal structure of the PHF8 Jumonji domain, an Nepsilon-methyl lysine demethylaseDimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugHDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeuticsVHL inactivation induces HEF1 and Aurora kinase AEpigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cellsRole of protein tyrosine phosphatases in cancerPreclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells.Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat.Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group studyPleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19bHistone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids.The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.A systems biology approach identifies molecular networks defining skeletal muscle abnormalities in chronic obstructive pulmonary diseaseRational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin AVorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and UnHistone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.Chemical genetics and its potential in cardiac stem cell therapy.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.CREB-binding protein controls response to cocaine by acetylating histones at the fosB promoter in the mouse striatum.Effects of endostatin and a new drug terpestacin against human neuroblastoma xenograft and cell lines.Histone deacetylase inhibitors: discovery and development as anticancer agents.Evaluation of the efficacy of radiation-modifying compounds using γH2AX as a molecular marker of DNA double-strand breaksAcetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors.Modulation of acetylation: creating a pro-survival and anti-inflammatory phenotype in lethal hemorrhagic and septic shock.Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation.Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer.Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition.HDAC inhibition and graft versus host diseaseThe histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.Polyphenols from green tea inhibit the growth of melanoma cells through inhibition of class I histone deacetylases and induction of DNA damage.Natural products synthesis: enabling tools to penetrate Nature's secrets of biogenesis and biomechanism.Synthesis of (S)-2-Boc-Amino-8-(R)-(tert-butyldimethylsilanyloxy) decanoic acid, a Precursor to the Unusual Amino Acid Residue of the Anticancer Agent Microsporin B.
P2860
Q24675749-76B5C340-1712-4FD1-8E0F-127C89BE5D82Q26746934-D42A76AE-D065-4D63-98A2-D44963064BC7Q27015931-38B33A8B-9513-4B1B-AA63-8CE4A3426360Q27315154-AA7B5B80-1C41-412D-8F54-32CDC82E09FBQ27658935-4DA651F7-A4A6-4B5C-8458-78E218C4D352Q28282479-47837173-8AB6-487C-856A-DB7D2D66A44CQ28290352-E8B5BBD7-CBB6-48CF-BBB0-D645CCB2183AQ28294037-F695F1F0-A261-4A8E-9777-43E623E33936Q28544442-01CE8814-224F-447A-B4A5-C2DEB6F6A44CQ28741003-944A6703-A0FF-4B6A-B5FA-294B484E4247Q30459589-6FB29B65-04D3-4582-B81D-36509BFBDBEAQ33344484-4F694001-1F5B-467E-877C-F7B08DF0B22BQ33375694-F04BD114-1882-49C6-A852-F2E4931C56A6Q33385966-3D9E22AD-B36F-439C-AF00-C36A0EB94FCBQ33398291-8431D18B-0483-4920-9BEA-E79508E3A1ECQ33632244-6909C790-E79C-4038-AD2A-1ECC1FCAAEA6Q33705588-010B2D0F-84DB-4265-857A-E071C365FFC4Q33747841-8780E5D0-BFAC-47E0-87C0-9A4B33695CAFQ33829390-2588DD58-5A54-4635-A2FE-29D3689BAFAFQ34016181-6755BAC4-372A-4B75-BAA7-155FB4EEF273Q34044049-F12F26C7-D05E-491A-B29D-B4C7E38DA96BQ34048411-0C17017C-7956-4223-8A1F-56EF83C705ACQ34093052-4E2D49D8-DC61-4806-A39F-AD0476DB5B56Q34183137-1348B868-438B-48A8-8055-B89F78C26D66Q34224278-48C92C01-C595-46EA-AED3-D95C313552AFQ34245266-3F844FE3-E009-4074-AF36-D31CDD7DEF99Q34373673-AC401D57-16D0-4D7B-A886-55245E96A333Q34470150-76ADD929-89E5-4E5D-94D6-20EA53983038Q34567095-B6254C36-89A0-488B-B31D-1D038C4B4ADFQ34626608-339AA711-44CB-40F4-9463-B1298B1883BCQ34635234-512FFD83-6E00-4891-87A8-6E568AA6E692Q34739990-08B51105-6665-4874-887A-5E425F1F675CQ34988874-0AF7C9B0-403E-4ED3-B069-9EC0F2CAD3EDQ35005604-A8172540-2474-4FB1-B70D-FD20639A80BCQ35016985-77D39915-1F7A-4D5E-8DD1-89633BBF2BF6Q35060679-7C66D8DA-CA9F-4FB7-920B-1D5E5BB8EAA3Q35133494-9E9483BB-3B6F-4D10-ACFB-F5622C740F09Q35184499-D32A89F0-7EF9-4968-B2CA-38EBB549616BQ35215703-1A050FEC-1D56-41F0-8816-D3E90A27E289Q35258648-53C9D3F7-7639-441D-BECF-BBC8AED4C335
P2860
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Drug insight: Histone deacetyl ...... beroylanilide hydroxamic acid.
@ast
Drug insight: Histone deacetyl ...... beroylanilide hydroxamic acid.
@en
type
label
Drug insight: Histone deacetyl ...... beroylanilide hydroxamic acid.
@ast
Drug insight: Histone deacetyl ...... beroylanilide hydroxamic acid.
@en
prefLabel
Drug insight: Histone deacetyl ...... beroylanilide hydroxamic acid.
@ast
Drug insight: Histone deacetyl ...... beroylanilide hydroxamic acid.
@en
P356
P1476
Drug insight: Histone deacetyl ...... beroylanilide hydroxamic acid.
@en
P2093
Paul A Marks
William Kevin Kelly
P304
P356
10.1038/NCPONC0106
P577
2005-03-01T00:00:00Z